Astex (ASTX) Says FDA Committee Won't Support Dacogen Benefit/Risk Profile; Stock to Resume at 2:05pm ET
Shares of Astex Pharma (Nasdaq: ASTX) are set to resume trading at 2:05pm ET following news the FDA's Oncologic Drugs Advisory Committee voted not to support the current Dacogen profile.
Data in partner Eisai’s sNDA for Dacogen for Injection did not support a favorable benefit-risk profile for the treatment of acute myeloid leukemia (AML) in adults 65 years of age or older who are not considered candidates for induction therapy.
Get immediate access to market moving news and alerts with StreetInsider.com Premium - FREE TRIAL!
Data in partner Eisai’s sNDA for Dacogen for Injection did not support a favorable benefit-risk profile for the treatment of acute myeloid leukemia (AML) in adults 65 years of age or older who are not considered candidates for induction therapy.
Get immediate access to market moving news and alerts with StreetInsider.com Premium - FREE TRIAL!
You May Also Be Interested In
- Pfizer (PFE) Axitinib Gets Positive Opinion from CHMP EMA
- Vertex Pharmaceuticals (VRTX) Gets Positive Opinion from CHMP for KALYDECO
- Dynasil (DYSL) Shares Halted Again Immediately Upon Resumption, Now Up 74%; Co. Enters Tech Pact with Mayo Clinic
Create E-mail Alert Related Categories
Corporate News, FDA, Trading HaltsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
